220 related articles for article (PubMed ID: 16721057)
1. DEK Expression is controlled by E2F and deregulated in diverse tumor types.
Carro MS; Spiga FM; Quarto M; Di Ninni V; Volorio S; Alcalay M; Müller H
Cell Cycle; 2006 Jun; 5(11):1202-7. PubMed ID: 16721057
[TBL] [Abstract][Full Text] [Related]
2. Lap2alpha expression is controlled by E2F and deregulated in various human tumors.
Parise P; Finocchiaro G; Masciadri B; Quarto M; Francois S; Mancuso F; Muller H
Cell Cycle; 2006 Jun; 5(12):1331-41. PubMed ID: 16760672
[TBL] [Abstract][Full Text] [Related]
3. The Complexity of DEK Signaling in Cancer Progression.
Teng Y; Lang L; Jauregui CE
Curr Cancer Drug Targets; 2018; 18(3):256-265. PubMed ID: 28530531
[TBL] [Abstract][Full Text] [Related]
4. The DEK oncoprotein binds to highly and ubiquitously expressed genes with a dual role in their transcriptional regulation.
Sandén C; Järvstråt L; Lennartsson A; Brattås PL; Nilsson B; Gullberg U
Mol Cancer; 2014 Sep; 13():215. PubMed ID: 25216995
[TBL] [Abstract][Full Text] [Related]
5. Role of the DEK oncogene in the development of squamous cell carcinoma.
Ishida K; Nakashima T; Shibata T; Hara A; Tomita H
Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741
[TBL] [Abstract][Full Text] [Related]
6. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
7. Regulation of DEK expression by AP-2α and methylation level of DEK promoter in hepatocellular carcinoma.
Qiao MX; Li C; Zhang AQ; Hou LL; Yang J; Hu HG
Oncol Rep; 2016 Oct; 36(4):2382-90. PubMed ID: 27499261
[TBL] [Abstract][Full Text] [Related]
8. Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias.
Karam M; Thenoz M; Capraro V; Robin JP; Pinatel C; Lancon A; Galia P; Sibon D; Thomas X; Ducastelle-Lepretre S; Nicolini F; El-Hamri M; Chelghoun Y; Wattel E; Mortreux F
Neoplasia; 2014 Jan; 16(1):21-30. PubMed ID: 24563617
[TBL] [Abstract][Full Text] [Related]
9. Melanoma proliferation and chemoresistance controlled by the DEK oncogene.
Khodadoust MS; Verhaegen M; Kappes F; Riveiro-Falkenbach E; Cigudosa JC; Kim DS; Chinnaiyan AM; Markovitz DM; Soengas MS
Cancer Res; 2009 Aug; 69(16):6405-13. PubMed ID: 19679545
[TBL] [Abstract][Full Text] [Related]
10. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
11. DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML).
Logan GE; Mor-Vaknin N; Braunschweig T; Jost E; Schmidt PV; Markovitz DM; Mills KI; Kappes F; Percy MJ
Blood Cells Mol Dis; 2015 Jan; 54(1):123-31. PubMed ID: 25128083
[TBL] [Abstract][Full Text] [Related]
12. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.
Adams AK; Bolanos LC; Dexheimer PJ; Karns RA; Aronow BJ; Komurov K; Jegga AG; Casper KA; Patil YJ; Wilson KM; Starczynowski DT; Wells SI
Oncotarget; 2015 Dec; 6(41):43395-407. PubMed ID: 26527316
[TBL] [Abstract][Full Text] [Related]
13. Control of tumorigenesis and chemoresistance by the DEK oncogene.
Riveiro-Falkenbach E; Soengas MS
Clin Cancer Res; 2010 Jun; 16(11):2932-8. PubMed ID: 20501624
[TBL] [Abstract][Full Text] [Related]
14. DEK oncogene is overexpressed during melanoma progression.
Riveiro-Falkenbach E; Ruano Y; García-Martín RM; Lora D; Cifdaloz M; Acquadro F; Ballestín C; Ortiz-Romero PL; Soengas MS; Rodríguez-Peralto JL
Pigment Cell Melanoma Res; 2017 Mar; 30(2):194-202. PubMed ID: 27893188
[TBL] [Abstract][Full Text] [Related]
15. The DEK oncoprotein and its emerging roles in gene regulation.
Sandén C; Gullberg U
Leukemia; 2015 Aug; 29(8):1632-6. PubMed ID: 25765544
[TBL] [Abstract][Full Text] [Related]
16. Regulation of histone acetyltransferase activity of p300 and PCAF by proto-oncogene protein DEK.
Ko SI; Lee IS; Kim JY; Kim SM; Kim DW; Lee KS; Woo KM; Baek JH; Choo JK; Seo SB
FEBS Lett; 2006 May; 580(13):3217-22. PubMed ID: 16696975
[TBL] [Abstract][Full Text] [Related]
17. DEK proto-oncogene expression interferes with the normal epithelial differentiation program.
Wise-Draper TM; Morreale RJ; Morris TA; Mintz-Cole RA; Hoskins EE; Balsitis SJ; Husseinzadeh N; Witte DP; Wikenheiser-Brokamp KA; Lambert PF; Wells SI
Am J Pathol; 2009 Jan; 174(1):71-81. PubMed ID: 19036808
[TBL] [Abstract][Full Text] [Related]
18. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.
Sandén C; Ageberg M; Petersson J; Lennartsson A; Gullberg U
BMC Cancer; 2013 Sep; 13():440. PubMed ID: 24073922
[TBL] [Abstract][Full Text] [Related]
19. DEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer.
Wang J; Sun L; Yang M; Luo W; Gao Y; Liu Z; Qiu X; Wang E
J Histochem Cytochem; 2013 Jul; 61(7):510-21. PubMed ID: 23571382
[TBL] [Abstract][Full Text] [Related]
20. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.
Privette Vinnedge LM; McClaine R; Wagh PK; Wikenheiser-Brokamp KA; Waltz SE; Wells SI
Oncogene; 2011 Jun; 30(24):2741-52. PubMed ID: 21317931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
